Trump says he may block stricter FDA guidelines for COVID-19 vaccine

Trump says he may block stricter FDA guidelines for COVID-19 vaccine

FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe
FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020. REUTERS/Dado Ruvic/File Photo

WASHINGTON: US President Donald Trump said on Wednesday (Sep 23) he may or may not approve any new, more stringent FDA standards for an emergency authorisation of a COVID-19 vaccine, saying such a proposal would appear political.

Trump has repeatedly said a vaccine for COVID-19, the disease caused by the coronavirus, could be ready for distribution ahead of the Nov 3 presidential election.

The Washington Post reported on Tuesday the US Food and Drug Administration would issue the guidance to boost transparency and public trust as health experts have become increasingly concerned the Trump administration might be interfering in the approval process to rush out a vaccine.

READ: US passes 200,000 COVID-19 deaths, weeks before election

Trump, however, questioned why a vaccine would need to be delayed and said such a proposal by the FDA would appear to be politically driven.

"We're looking at that and that has to be approved by the White House. We may or may not approve it," Trump told a White House news conference, when asked about the Post report.

"That sounds like a political move. Because when you have Pfizer, Johnson & Johnson, Moderna, these great companies, coming up with the vaccines, and they've done testing and everything else, I'm saying why would they have to be adding great length to the process."

Trump added he had "tremendous trust" in those companies.

Few vaccine developers were expected to have definitive trial results before the presidential election. Pfizer had been the exception, although its timetable could slip with new guidance.

Moderna has said it is unlikely to have data in October. AstraZeneca's trial in the United States is halted while investigators try to determine whether a serious neurological problem suffered by one participant in the company's UK trial was caused by the vaccine.

Commentary: The challenge of keeping COVID-19 vaccines at sub-zero temperatures during distribution

US Food and Drug Administration head Stephen Hahn did not directly address the Washington Post report when testifying before the Senate earlier on Wednesday.

But he did say regulators would likely provide additional information on the emergency use authorisation process.

At the same hearing, US Centers for Disease Control and Prevention head Robert Redfield said he expects there to be about 700 million doses of vaccines available by late March or April, enough for 350 million people.

"I think that's going to take us April, May, June, you know, possibly July, to get the entire American public completely vaccinated," Redfield told the US Senate Health, Education, Labor and Pensions Committee.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/jt

Bookmark